UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 3, 2023, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished herewith:
99.1 |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Dynavax Technologies Corporation |
|
|
|
|
Date: |
August 3, 2023 |
By: |
/s/ Kelly MacDonald |
|
|
|
Kelly MacDonald |
Exhibit 99.1
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
EMERYVILLE, CA – August 3, 2023 – Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2023.
“This quarter’s impressive HEPLISAV-B revenue growth reflects the continued expansion of the hepatitis B vaccine market and our team’s success in capturing market share. As a result of the strong HEPLISAV-B performance in the first half of 2023, which exceeded expectations, and the growing enthusiasm that we see in the market, we are significantly raising our revenue expectations for the full year,” said Ryan Spencer, Chief Executive Officer of Dynavax.
BUSINESS UPDATES
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]
HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S., the European Union and Great Britain that enables series completion with only two doses in one month. Hepatitis B vaccination is universally recommended for adults aged 19-59 in the U.S.
Clinical Pipeline
Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018® adjuvant, which has demonstrated its ability to enhance the immune response with a favorable tolerability profile in a wide range of clinical trials and real-world commercial use.
Shingles vaccine program:
Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Tdap vaccine program:
Tdap-1018 is an investigational vaccine candidate intended for active booster immunization against tetanus, diphtheria, and pertussis (Tdap).
Plague vaccine program:
DV2-PLG-01 is a plague (rF1V) vaccine candidate currently in a Phase 2 clinical trial in collaboration with, and fully funded by, the U.S. Department of Defense.
CORPORATE UPDATES
SECOND QUARTER 2023 FINANCIAL HIGHLIGHTS
Total Revenues and Product Revenue, Net.
Cost of Sales - Product. Total cost of sales – product for the second quarter of 2023 decreased to $13.5 million, compared to $83.4 million in the second quarter of 2022. The decrease is due to no CpG 1018 adjuvant cost of sales – product for the second quarter of 2023 compared to $73.1 million in the second quarter of 2022. Cost of sales - product for HEPLISAV-B in the second quarter of 2023 increased to $13.5 million, compared to $10.3 million for the second quarter of 2022. The increase was due to higher sales volume driven by continued improvement in HEPLISAV-B market share and utilization.
Research and Development Expenses (R&D). R&D expenses for the second quarter of 2023 increased to $13.0 million, compared to $9.7 million for the second quarter of 2022. The increase was primarily driven by continued investments in our product candidates utilizing CpG 1018 adjuvant through preclinical and clinical collaborations and additional discovery efforts.
Selling, General, and Administrative Expenses (SG&A). SG&A expenses for the second quarter of 2023 increased to $37.1 million, compared to $36.2 million for the second quarter of 2022. The increase was primarily driven by higher compensation and related personnel costs and an overall increase in targeted commercial and marketing efforts to increase market share and maximize the ACIP’s universal recommendation.
Net income. GAAP net income was $3.4 million, or $0.03 per share (basic and diluted) in the second quarter of 2023, compared to GAAP net income of $128.8 million, or $1.02 per share (basic) and $0.87 per share (diluted) in the second quarter of 2022.
Cash and Marketable Securities. Cash, cash equivalents and marketable securities were $681.5 million as of June 30, 2023.
2023 FINANCIAL GUIDANCE
Full year 2023 financial guidance has been revised to consist of the following expectations:
Conference Call and Webcast Information
Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link at https://investors.dynavax.com/events-presentations and under the “Upcoming Events” section, click on "Listen to webcast." It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
Important U.S. Product Information
HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.
For full U.S. Prescribing Information for HEPLISAV-B, please visit the following website at https://www.heplisavbhcp.com, and click the “Prescribing Information” link in the “Important Safety Information” section.
Important U.S. Safety Information (ISI)
Do not administer HEPLISAV-B to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23% to 39%), fatigue (11% to 17%), and headache (8% to 17%).
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “will,” “may,” “plan,” “project,” “potential,” “seek,” “should,” “think,” “will,” “would” and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding financial guidance, the development and potential approval of vaccines containing CpG 1018 adjuvant by us or by our collaborators, the timing of IND filings, the timing of initiation and completion of clinical studies and the publication of results. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including, the risk that actual demand for our products may differ from our expectations, risks related to the timing of completion and results of current clinical studies, risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, whether use of CpG 1018 adjuvant will prove to be
beneficial in these vaccines, as well as other risks detailed in the "Risk Factors" section of our Annual Report on Form 10-Q for the quarter ended June 30, 2023 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
DYNAVAX TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
|
Three Months Ended |
|
Six Months Ended |
||||||||||
|
June 30, |
|
June 30, |
||||||||||
|
2023 |
|
|
2022 |
|
2023 |
|
|
2022 |
||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenues, net |
$ |
56,440 |
|
|
$ |
255,320 |
|
$ |
99,891 |
|
|
$ |
367,647 |
Other revenue |
|
3,809 |
|
|
|
1144 |
|
|
7,283 |
|
|
|
2809 |
Total revenues |
|
60,249 |
|
|
|
256,464 |
|
|
107,174 |
|
|
|
370,456 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales – product |
|
13,537 |
|
|
|
83,369 |
|
|
28,249 |
|
|
|
123,331 |
Research and development |
|
13,046 |
|
|
|
9,689 |
|
|
26,651 |
|
|
|
20,784 |
Selling, general and administrative |
|
37,071 |
|
|
|
36,179 |
|
|
73,614 |
|
|
|
68,351 |
Gain on sale of assets |
|
- |
|
|
|
(1,000) |
|
|
- |
|
|
|
(1,000) |
Bad debt expense |
|
- |
|
|
|
- |
|
|
12,313 |
|
|
|
- |
Total operating expenses |
|
63,654 |
|
|
|
128,237 |
|
|
140,827 |
|
|
|
211,466 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from operations |
|
(3,405) |
|
|
|
128,227 |
|
|
(33,653) |
|
|
|
158,990 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
7,378 |
|
|
|
765 |
|
|
13,975 |
|
|
|
1,026 |
Interest expense |
|
(1,688) |
|
|
|
(1,683) |
|
|
(3,374) |
|
|
|
(3,363) |
Sublease income |
|
1,993 |
|
|
|
2,025 |
|
|
3,591 |
|
|
|
3,634 |
Change in fair value of warrant liability |
|
- |
|
|
|
- |
|
|
- |
|
|
|
1,801 |
Other |
|
(71) |
|
|
|
40 |
|
|
(48) |
|
|
|
145 |
Net income (loss) before income taxes |
|
4,207 |
|
|
|
129,374 |
|
|
(19,509) |
|
|
|
162,233 |
Provision for income taxes |
|
(776) |
|
|
|
(619) |
|
|
(1,392) |
|
|
|
(619) |
Net income (loss) |
$ |
3,431 |
|
|
$ |
128,755 |
|
$ |
(20,901) |
|
|
$ |
161,614 |
Net income (loss) per share attributable to common |
|
|
|
|
|
|
|
|
|
|
|
|
|
stockholders: |
|
||||||||||||
Basic |
$ |
0.03 |
|
|
$ |
1.02 |
|
$ |
(0.16) |
|
|
$ |
1.29 |
Diluted |
$ |
0.03 |
|
|
$ |
0.87 |
|
$ |
(0.16) |
|
|
$ |
1.08 |
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
128,625 |
|
|
|
126,347 |
|
|
128,275 |
|
|
|
125,456 |
Diluted |
|
152,142 |
|
|
|
149,905 |
|
|
128,275 |
|
|
|
149,821 |
DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)
|
|
June 30, |
|
December 31, |
||
|
|
|||||
|
|
2023 |
|
2022 |
||
Assets |
|
|
|
|
|
|
Cash, cash equivalents and marketable securities |
|
$ |
681,525 |
|
$ |
624,395 |
Inventories |
|
|
53,088 |
|
|
59,446 |
Other current assets |
|
|
62,847 |
|
|
233,144 |
Total current assets |
|
|
797,460 |
|
|
916,985 |
Total non-current assets |
|
|
138,972 |
|
|
68,865 |
Total assets |
|
$ |
936,432 |
|
$ |
985,850 |
|
|
|
|
|
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
Total current liabilities |
|
$ |
44,862 |
|
$ |
150,074 |
Total long-term liabilities |
|
|
314,365 |
|
|
254,763 |
Stockholders’ equity |
|
|
577,205 |
|
|
581,013 |
Total liabilities and stockholders’ equity |
|
$ |
936,432 |
|
$ |
985,850 |